DOCSLIB.ORG

University of Milano-Bicocca Department of Medicine and Surgery Circulating Levels of Soluble Receptor for Advanced Glycation En

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Milano-Bicocca Department of Medicine and Surgery Circulating Levels of Soluble Receptor for Advanced Glycation En University of Milano-Bicocca Department of medicine and surgery PhD PROGRAM IN TRANSLATIONAL AND MOLECULAR MEDICINE DIMET Circulating levels of soluble Receptor for Advanced Glycation End-products (sRAGE) decrease with aging and may predict age- related cardiac remodeling Coordinator: Prof. Andrea Biondi Tutor: Prof. Giulio Pompilio Co-tutor: Dr. Angela Raucci Dr. Filippo Zeni Matr N°: 787963 XXIX CYCLE Academic Year 2015-2016 Table of contents Chapter 1……………..……………………………………………………………….3 General Introduction ............................................................................. 4 Aging ............................................................................................................ 4 Molecular mechanisms of aging ................................................................ 5 DNA Damage and instability .............................................................................. 5 DNA damage and apoptosis ............................................................................... 6 Telomere shortening ............................................................................................. 7 Epigenetic Alterations .......................................................................................... 8 Mitochondrial dysfunction .............................................................................. 10 Stem cells exhaustion ......................................................................................... 11 Biomarkers of aging ........................................................................................... 12 Sex-Dependent Differences in aging ..................................................... 15 The heart: basic anatomy ................................................................... 18 Cardiac Aging .......................................................................................... 22 Vascular aging ............................................................................................... 23 Cardiac Changes During Aging ................................................................ 25 Morphologic changes ......................................................................................... 25 Systolic functions ................................................................................................. 28 Diastolic functions ............................................................................................... 29 Conduction system .............................................................................................. 30 Animal models ...................................................................................................... 32 Molecular changes ............................................................................................... 33 Altered Nutrient and Growth Signaling ............................................................... 33 Mitochondrial Oxidative Damage and Mitochondrial Dysfunction ......... 35 Adverse Extracellular Matrix (ECM) Remodeling ........................................... 36 Impaired Calcium Homeostasis ............................................................................... 38 Circulating biomarkers of cardiac aging .................................................... 40 MicroRNAs ........................................................................................................................ 40 Circulating factors ......................................................................................................... 41 Sex and age-related cardiac remodeling ............................................. 44 The Receptor for Advanced Glycation End Products (RAGE) 46 Splice Variants of RAGE .............................................................................. 51 1 Production of sRAGE via Proteolytic Cleavage of RAGE ................. 53 Modulation of sRAGE levels ...................................................................... 54 RAGE ligands .................................................................................................. 57 AGEs .......................................................................................................................... 57 High Mobility Group (HMG) Box-1 ............................................................... 59 S100 Proteins and RAGE................................................................................... 62 RAGE, aging and heart ................................................................................ 64 sRAGE, aging and heart .............................................................................. 66 Scope of the thesis ................................................................................. 70 References ............................................................................................... 72 Chapter 2 .................................................................................................. 91 Abstract .................................................................................................... 92 Introduction ............................................................................................ 95 Materials and Methods ........................................................................ 99 Human study .................................................................................................. 99 Study population .................................................................................................. 99 Human Elisa assays ............................................................................................. 99 Statistical analysis ............................................................................................ 100 Animal study ............................................................................................... 100 Animals ................................................................................................................. 100 Echocardiography ............................................................................................ 101 Western Blotting (WB) ................................................................................... 101 Immunoistochemistry (IHC) ........................................................................ 102 Quantitative RT-PCR (qRT-PCR) ................................................................ 103 Isolation of Mouse Cardiomyocytes .......................................................... 104 Evaluation of CMs cross sectional area ................................................... 105 Mouse ELISA assay ........................................................................................... 106 Statistical analysis ............................................................................................ 106 Gene expression analysis .............................................................................. 107 Results .................................................................................................... 111 Circulating levels of sRAGE decrease in healthy subjects during aging ............................................................................................................... 111 RAGE ligands behavior during human healthy aging................... 115 Circulating levels of sRAGE decrease with aging in mice............ 116 2 Serum levels of sRAGE correlate with age-associated cardiac changes ......................................................................................................... 118 Cardiac levels of RAGE isoforms during aging ................................ 121 Rage-/- mice show an increase of LV dimensions during aging 123 Rage-/- mice show enhanced cardiac fibrosis but not hypertrophy with aging .......................................................................... 125 Rage-/- mice show higher expression of heart failure markers .......................................................................................................................... 128 RAGE and aging influence LV genes expression ............................. 129 Differentially expressed genes correlates with cardiac mice phenotype .................................................................................................... 131 Discussion ............................................................................................. 134 References ............................................................................................ 144 Supplementary Information .......................................................... 149 Chapter 3 ............................................................................................... 154 Summary ............................................................................................... 154 Translational significance and future perspectives .............. 156 Publications ......................................................................................... 160 References ............................................................................................ 169 3 General Introduction Aging Population aging is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to an estimated 2 billion people by 20501. The substantial gain of approximately 30 years in life expectancy in western world countries such as Spain and Italy and even larger gains in Japan, stands out as one of the most important achievement of the 20th century. The oldest-old group (aged >85 years) has been, during the last years, the
Load more

Recommended publications
  • Genome-Wide Analysis of Host-Chromosome Binding Sites For
    Lu et al. Virology Journal 2010, 7:262 http://www.virologyj.com/content/7/1/262 RESEARCH Open Access Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Fang Lu1, Priyankara Wikramasinghe1, Julie Norseen1,2, Kevin Tsai1, Pu Wang1, Louise Showe1, Ramana V Davuluri1, Paul M Lieberman1* Abstract The Epstein-Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) protein is required for the establishment of EBV latent infection in proliferating B-lymphocytes. EBNA1 is a multifunctional DNA-binding protein that stimulates DNA replication at the viral origin of plasmid replication (OriP), regulates transcription of viral and cellular genes, and tethers the viral episome to the cellular chromosome. EBNA1 also provides a survival function to B-lymphocytes, potentially through its ability to alter cellular gene expression. To better understand these various functions of EBNA1, we performed a genome-wide analysis of the viral and cellular DNA sites associated with EBNA1 protein in a latently infected Burkitt lymphoma B-cell line. Chromatin-immunoprecipitation (ChIP) combined with massively parallel deep-sequencing (ChIP-Seq) was used to identify cellular sites bound by EBNA1. Sites identified by ChIP- Seq were validated by conventional real-time PCR, and ChIP-Seq provided quantitative, high-resolution detection of the known EBNA1 binding sites on the EBV genome at OriP and Qp. We identified at least one cluster of unusually high-affinity EBNA1 binding sites on chromosome 11, between the divergent FAM55 D and FAM55B genes. A con- sensus for all cellular EBNA1 binding sites is distinct from those derived from the known viral binding sites, sug- gesting that some of these sites are indirectly bound by EBNA1.
    [Show full text]
  • Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) Catalog # CD7-H522b
    Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) Catalog # CD7-H522b Synonym Formulation CD27,TNFRSF7,S152,T14,Tp55 Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is Source added as protectant before lyophilization. Human CD27, His Tag (CD7-H522b) is expressed from human 293 cells Contact us for customized product form or formulation. (HEK293). It contains AA Thr 21 - Ile 192 (Accession # P26842-1). Reconstitution Predicted N-terminus: Thr 21 Molecular Characterization Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA. Storage This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.1 kDa. The protein migrates as 35-45 For long term storage, the product should be stored at lyophilized state at -20°C kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. or lower. Please avoid repeated freeze-thaw cycles. Endotoxin This product is stable after storage at: Less than 1.0 EU per μg by the LAL method. -20°C to -70°C for 12 months in lyophilized state; ° Purity -70 C for 3 months under sterile conditions after reconstitution. >90% as determined by SDS-PAGE. SDS-PAGE SEC-MALS Human CD27, His Tag on SDS-PAGE under reducing (R) condition. The gel The purity of Human CD27, His Tag (Cat. No. CD7-H522b) was more than was stained overnight with Coomassie Blue. The purity of the protein is greater 85% and the molecular weight of this protein is around 38-48 kDa verified by than 90%.
    [Show full text]
  • Antigen-Specific Memory CD4 T Cells Coordinated Changes in DNA
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology The Journal of Immunology published online 18 March 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/03/17/jimmun ol.1202267 Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto, Katsumi Ogoshi, Atsushi Sasaki, Jun Abe, Wei Qu, Yoichiro Nakatani, Budrul Ahsan, Kenshiro Oshima, Francis H. W. Shand, Akio Ametani, Yutaka Suzuki, Shuichi Kaneko, Takashi Wada, Masahira Hattori, Sumio Sugano, Shinichi Morishita and Kouji Matsushima J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Author Choice option Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Freely available online through http://www.jimmunol.org/content/suppl/2013/03/18/jimmunol.120226 7.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Author Choice Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. Published March 18, 2013, doi:10.4049/jimmunol.1202267 The Journal of Immunology Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto,*,†,‡ Katsumi Ogoshi,* Atsushi Sasaki,† Jun Abe,* Wei Qu,† Yoichiro Nakatani,† Budrul Ahsan,x Kenshiro Oshima,† Francis H.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Siva1 Suppresses Epithelial–Mesenchymal Transition and Metastasis of Tumor Cells by Inhibiting Stathmin and Stabilizing Microtubules
    Siva1 suppresses epithelial–mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules Nan Lia, Peng Jiangb, Wenjing Dub, Zhengsheng Wuc, Cong Lia, Mengran Qiaoa, Xiaolu Yangb,1, and Mian Wua,1 aHefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China; bDepartment of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and cDepartment of pathology, Anhui Medical University, Hefei, Anhui 230032, China Edited by Joan S. Brugge, Harvard Medical School, Boston, MA, and approved June 20, 2011 (received for review November 19, 2010) Epithelial–mesenchymal transition (EMT) enables epithelial cells to still not clear, nor is the regulation of stathmin phosphorylation acquire motility and invasiveness that are characteristic of mesen- well understood. In this study, we find that stathmin interacts with chymal cells. It plays an important role in development and tumor Siva1, a molecule involved in aspects of apoptosis regulation (15– cell metastasis. However, the mechanisms of EMT and their dys- 18). Our study reveals a critical role for stathmin and microtubule function in cancer cells are still not well understood. Here we re- dynamics in promoting EMT. We further show that Siva1 is an port that Siva1 interacts with stathmin, a microtubule destabilizer. important negative regular of stathmin and that the down-regu- Siva1 inhibits stathmin’s activity directly as well as indirectly lation of Siva1 may promote EMT and tumor cell dissemination. through Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation of stathmin at Ser16.
    [Show full text]
  • Regulation of Rhob Gene Expression During Tumorigenesis and Aging Process and Its Potential Applications in These Processes
    cancers Review Regulation of RhoB Gene Expression during Tumorigenesis and Aging Process and Its Potential Applications in These Processes Eutiquio Gutierrez 1,2,*, Ian Cahatol 1,3, Cedric A.R. Bailey 1,4, Audrey Lafargue 5 , Naming Zhang 6, Ying Song 6, Hongwei Tian 6, Yizhi Zhang 6, Ryan Chan 6, Kevin Gu 6, Angel C.C. Zhang 7, James Tang 7, Chunshui Liu 7, Nick Connis 6, Phillip Dennis 6 and 6, Chunyu Zhang y 1 College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, 309 E 2nd Street, Pomona, CA 91766, USA 2 Department of Internal Medicine, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90509, USA 3 Department of Graduate Medical Education, Community Memorial Health System, 147 N Brent Street, Ventura, CA 93003, USA 4 Department of Pathology and Immunology, Washington University School of Medicine, 509 S Euclid Avenue, St. Louis, MO 63110, USA 5 Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA 6 Department of Oncology, The Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA 7 Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA * Correspondence: [email protected] Deceased: This paper is dedicated to Dr. Chunyu Zhang, the principal investigator of this research. y Received: 25 April 2019; Accepted: 6 June 2019; Published: 13 June 2019 Abstract: RhoB, a member of the Ras homolog gene family and GTPase, regulates intracellular signaling pathways by interfacing with epidermal growth factor receptor (EGFR), Ras, and phosphatidylinositol 3-kinase (PI3K)/Akt to modulate responses in cellular structure and function.
    [Show full text]
  • Toward Understanding the Role of P53 in Cardiovascular Diseases
    J. Biomedical Science and Engineering, 2013, 6, 209-212 JBiSE http://dx.doi.org/10.4236/jbise.2013.62A025 Published Online February 2013 (http://www.scirp.org/journal/jbise/) Toward understanding the role of p53 in cardiovascular diseases Mohanalatha Chandrasekharan1, Silvia Vasquez2, Rajesh Kumar Galimudi3, Prashanth Suravajhala1 1Bioclues.org, IKP Knowledge Park, Secunderabad, India 2Instituto Peruano de Energía Nuclear, Centro Nuclear RACSO, Lima, Perú 3Department of Genetics, Osmania University, Hyderabad, India Email: [email protected], [email protected], [email protected], [email protected] Received 14 November 2012; revised 15 December 2012; accepted 22 December 2012 ABSTRACT hypertrophy to heart failure through the suppression of hypoxia inducible factor-1 (HIF-1), which regulates an- Tumour suppressor protein 53 (TP53 or simply p53) giogenesis in the hypertrophied heart. In addition, as p53 is a well known protein linked to apoptosis, cell sig- is known to promote apoptosis, which in turn is involved nalling, cascading and several myriad functions in in heart failure, p53 might be a key molecule in trigger- cells. Many diseases are linked to p53 though analysis ing the development of heart failure from multiple me- show only 216 interaction partners. Whether p53 chanisms [5,6]. While p53 can modulate the activity and plays an important role in cardiovascular diseases expression of some other proteins have been recently (CVD) remains uncertain. Through this bioinfor- studied, whether or not there are potentially beneficial matical analysis, we propose that p53 might play a effects remains to be understood. The actions of the ag- major role in CVD whilst being linked to Hypoxia ing proteins on the CVD have been well studied [7] with and Lupus.
    [Show full text]
  • 1017372108.Full.Pdf
    Siva1 suppresses epithelial–mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules Nan Lia, Peng Jiangb, Wenjing Dub, Zhengsheng Wuc, Cong Lia, Mengran Qiaoa, Xiaolu Yangb,1, and Mian Wua,1 aHefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China; bDepartment of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and cDepartment of pathology, Anhui Medical University, Hefei, Anhui 230032, China Edited by Joan S. Brugge, Harvard Medical School, Boston, MA, and approved June 20, 2011 (received for review November 19, 2010) Epithelial–mesenchymal transition (EMT) enables epithelial cells to still not clear, nor is the regulation of stathmin phosphorylation acquire motility and invasiveness that are characteristic of mesen- well understood. In this study, we find that stathmin interacts with chymal cells. It plays an important role in development and tumor Siva1, a molecule involved in aspects of apoptosis regulation (15– cell metastasis. However, the mechanisms of EMT and their dys- 18). Our study reveals a critical role for stathmin and microtubule function in cancer cells are still not well understood. Here we re- dynamics in promoting EMT. We further show that Siva1 is an port that Siva1 interacts with stathmin, a microtubule destabilizer. important negative regular of stathmin and that the down-regu- Siva1 inhibits stathmin’s activity directly as well as indirectly lation of Siva1 may promote EMT and tumor cell dissemination. through Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation of stathmin at Ser16.
    [Show full text]
  • Human CD27 / TNFRSF7 Protein
    Human CD27 / TNFRSF7 Protein Catalog # AMS.CD7-H522b For Research Use Only CD7-H522b-STC2 Description Source Human CD27 (AMS.CD7-H522b) is expressed from human 293 cells (HEK293). It contains AA Thr 21 - Ile 192 (Accession # P26842-1). Predicted N-terminus: Thr 21 Predicted N-terminus Thr 21 Protein Structure Molecular This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.1 kDa. The protein migrates as 35- Characterization 45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. Endotoxin Less than 1.0 EU per μg by the LAL method. Purity >90% as determined by SDS-PAGE. Formulation and Storage Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. Reconstitution Please see Certificate of Analysis for specific instructions.For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA. Storage For long term storage, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: ● 4-8℃ for 12 months in lyophilized state; ● -70℃ for 3 months under sterile conditions after reconstitution. Background Background CD Antigen CD27 is also known as Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), which belongs to TNF- receptor superfamily. CD27 / TNFRSF7 is found in most T-lymphocytes. CD27 / TNFRSF7 is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis.
    [Show full text]
  • Helicobacter Pylori: Preying on SIVA for Survival in the Stomach
    The Journal of Clinical Investigation COMMENTARY Helicobacter pylori: preying on SIVA for survival in the stomach José B. Sáenz1 and Jason C. Mills1,2,3 1Division of Gastroenterology, Department of Internal Medicine, 2Department of Developmental Biology, and 3Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. infected with cagA-positive strains of H. pylori showed increased XIAP phosphor- Infection with the Gram-negative bacterium Helicobacter pylori remains the ylation (the activated form of the protein) most important modifiable risk factor for the development of gastric cancer, and decreased SIVA1 compared with unin- a leading cause of cancer-related deaths worldwide. How the interactions fected individuals or those infected with between H. pylori and its host shape the gastric environment during chronic cagA-negative strains (5). This article thus infection warrants further investigation. In this issue of the JCI, Palrasu identifies yet another key function of the et al. used human cell lines and mouse models to provide mechanistic versatile CagA protein (10), in this case insight into H. pylori’s ability to delay apoptosis in gastric epithelial cells promoting H. pylori pathogenesis by sub- by actively driving the degradation of a proapoptotic factor, SIVA1. Their verting established host apoptotic defense findings suggest that promoting the survival of gastric epithelial cells has mechanisms (5). implications not only for H. pylori pathogenesis but for host tumorigenesis. Apoptosis in the stomach The Palrasu et al. study (5) forces us to reconsider the evolutionary tit-for-tat that exists between H. pylori and the human Helicobacter pylori overcomes changes in epithelial cell proliferation, stomach.
    [Show full text]
  • Elucidating the IGFBP2 Signaling Pathway in Glioma Development and Progression
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2012 Elucidating the IGFBP2 signaling pathway in glioma development and progression Kristen M. Holmes Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Cancer Biology Commons, and the Medicine and Health Sciences Commons Recommended Citation Holmes, Kristen M., "Elucidating the IGFBP2 signaling pathway in glioma development and progression" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 222. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/222 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. Elucidating the IGFBP2 signaling pathway in glioma development and progression By Kristen M. Holmes, M.S. APPROVED: ___________________________ Wei Zhang, Ph.D.,
    [Show full text]
  • A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression
    Supplementary Materials A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression Table S1. Statistically significant DEGs (Adj. p-value < 0.01) derived from meta-analysis for samples irradiated with high doses of HZE particles, collected 6-24 h post-IR not common with any other meta- analysis group. This meta-analysis group consists of 3 DEG lists obtained from DGEA, using a total of 11 control and 11 irradiated samples [Data Series: E-MTAB-5761 and E-MTAB-5754]. Ensembl ID Gene Symbol Gene Description Up-Regulated Genes ↑ (2425) ENSG00000000938 FGR FGR proto-oncogene, Src family tyrosine kinase ENSG00000001036 FUCA2 alpha-L-fucosidase 2 ENSG00000001084 GCLC glutamate-cysteine ligase catalytic subunit ENSG00000001631 KRIT1 KRIT1 ankyrin repeat containing ENSG00000002079 MYH16 myosin heavy chain 16 pseudogene ENSG00000002587 HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 ENSG00000003056 M6PR mannose-6-phosphate receptor, cation dependent ENSG00000004059 ARF5 ADP ribosylation factor 5 ENSG00000004777 ARHGAP33 Rho GTPase activating protein 33 ENSG00000004799 PDK4 pyruvate dehydrogenase kinase 4 ENSG00000004848 ARX aristaless related homeobox ENSG00000005022 SLC25A5 solute carrier family 25 member 5 ENSG00000005108 THSD7A thrombospondin type 1 domain containing 7A ENSG00000005194 CIAPIN1 cytokine induced apoptosis inhibitor 1 ENSG00000005381 MPO myeloperoxidase ENSG00000005486 RHBDD2 rhomboid domain containing 2 ENSG00000005884 ITGA3 integrin subunit alpha 3 ENSG00000006016 CRLF1 cytokine receptor like
    [Show full text]